Institutional news
<p>La Dra. Cristina Mayor-Ruiz.</p>
3 Mar 2021

The programme seeks to enhance the production of new drugs through a powerful research programme in Chemical Biology that will allow the creation of a chemical biology hub in Barcelona.

By supporting the appointment of two new Junior Group Leaders, the programme has facilitated the setup of two new research groups, one at IRB Barcelona and the other at IBEC.

IRB Barcelona's commitment to talented young female scientists takes shape with the appointment of Dr. Cristina Mayor-Ruiz, who will be leading a scientific project with wide applications in patients devoted to the innovative technique of targeted protein degradation.

Institutional news
<p>ENABLECARES participants of the kick-off meeting held on 11 February 2021.</p>
2 Mar 2021

Funded under the Science with and for Society Programme of Horizon 2020, ENABLECARES will deliver high-level training in open science, entrepreneurship and other relevant transferable skills to young scientists in Europe.

Building on the expertise of IRB Barcelona's Innovation Department and Radboud University on entrepreneurship and Open Science, ENABLECARES will implement two training curricula in these subjects (nodes) at all four partners through co-creation and Train-the-Trainers strategies.

Scientific news
<p>Drosophila's brain exhibiting the ring gland, the equivalent to the human's prothoracic gland, responsible for steroidal hormone production.</p>
22 Feb 2021

Conducted on the fly Drosophila, the study shows that tumours caused by chromosomal instability delay entry into the adult phase.

The tumours produce the Upd3 protein (equivalent to human Interleukin-6) to block the production of developmental steroid hormones.

The work of IRB Barcelona's Growth Control and Development laboratory has been published in the journal Current Biology.

Institutional news
15 Feb 2021

The ICREA Acadèmia Award allows university professors to prioritise their dedication to research for 5 years.

The Cell Signaling laboratory, headed by Dr. Eulàlia de Nadal and Dr. Francesc Posas, studies cell adaptation response to stress. 


Institutional news
11 Feb 2021

This day promotes equal access to and full participation in science for women and girls.

Outreach activities are held focused on making the work of female researchers visible and encouraging girls to have these role models.

In the context of this day, IRB Barcelona shares an example of the visibility of the women scientists: girls and boys at the Pau Casals de Gracia school (Barcelona)  have named their class after the researcher Núria López-Bigas.

Scientific news
<p>Tracheal cells of Drosophila larvae, destined to form the adult tissue structures  (Giannios, IRB Barcelona)</p>
9 Feb 2021

Experiments carried out in the Drosophila fly have led to the identification of the headcase (hdc) gene as pivotal for adult progenitor cells, allowing them to undergo metamorphosis and give rise to adult tissue structures.

The study by IRB Barcelona’s Development and Morphogenesis in Drosophila lab has been published in PLOS Genetics.

Institutional news
4 Feb 2021

The 5-year research project involves 14 organisations in seven EU countries and is funded by €15 M from the EU.

The Genome Data Science lab, led by ICREA researcher Fran Supek, will analyse the evolution of ovarian tumours to develop computational models for predicting treatment resistance.


Institutional news
2 Feb 2021

Key for biomedical research, this new piece of unique and exclusive technology allows non-invasive visualisation of organ physiology and alterations.

More than 6,300 people have participated in the #MetastasisChallenge, which aims to raise €5 million to support research into metastasis—the main cause of cancer deaths.


Institutional news
29 Jan 2021

Xavier Salvatella's laboratory at IRB Barcelona receives €180,000 to develop new drugs against prostate cancer.

The AECC Innova projects are focused on technology transfer and aim to get research results to the patient faster.


Institutional news
21 Jan 2021

The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing.

Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis.

The capital increase is intended to complete regulatory development to commercialize next year.

Inbiomotion’s product addresses a significant companion diagnostics market globally.